Clinical Trial Update: A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study of the investigational agent SAR245409 in lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• SAR245409

Snippet

Sponsor: Sanofi | Conditions: Lymphoma | Phase 2 | Status: COMPLETED